Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31456438)

  • 1. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
    Sheikh S; Kuruvilla J
    Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
    Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
    Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Xu-Monette ZY; Zhou J; Young KH
    Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
    Hradska K; Kascak M; Hajek R; Jelinek T
    Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
    [No Abstract]   [Full Text] [Related]  

  • 8. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
    Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
    [No Abstract]   [Full Text] [Related]  

  • 10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for the treatment of cervical cancer.
    Marret G; Borcoman E; Le Tourneau C
    Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Immune System Alterations in Hodgkin Lymphoma.
    Grover NS; Savoldo B
    Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for the treatment of Hodgkin Lymphoma.
    Al Hadidi SA; Lee HJ
    Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF
    Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
    Falchi L
    Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 blockade in renal cell cancer.
    Beckermann KE; Johnson DB; Sosman JA
    Expert Rev Clin Immunol; 2017 Jan; 13(1):77-84. PubMed ID: 27426025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.